menu toggle
Thursday, November 26 - Friday, November 27
Cencora will be closed on Thursday, November 26 in observance of the Thanksgiving holiday. There will be no deliveries on this day and our Customer Service and Customer Systems Support teams will be unavailable. Our offices will also be closed on Friday, November 27. While deliveries for non-refrigerated product will be attempted on Friday, our offices will be closed. Customer Service may be limited and Customer System Support will also be limited and available by email only. Please review our full holiday schedule for more detailed information and to plan your orders accordingly.

May 26, 2022

Now available PEMETREXED

PEMETREXED for injection is a folate analog metabolic inhibitor indicated:

  • in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. (1.1)
  • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). (1.1)
  • as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (1.1)
  • as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. (1.1) Limitations of Use: Pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. (1.1)
  • initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. (1.2)

 

Please see full prescribing information here and here.

We are NABP accredited